GlobeNewswire Inc | Oct 15, 2020 07:00AM EDT

October 15, 2020

GAITHERSBURG, Md., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutics for liver disease, today announced that management will present at the following upcoming virtual investor conferences:

-- H.C. Wainwright Hepatitis B Virus (HBV) Virtual ConferenceTuesday, October 20, 2020 1:30 pm EDT

-- B. Riley Securities Liver Disease SymposiumThursday, October 29, 2020

The H.C. Wainwright HBV presentation will be webcast and can be accessed by visiting the investor relations section of the company's website at www.altimmune.com under Events / Presentations.

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. The Companys diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID), anthrax (NasoShield) and influenza (NasoVAX); an intranasal immune modulating therapeutic for COVID-19 (T-COVID); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell). For more information on Altimmune, please visitwww.altimmune.com.

Investor Contacts

Stacey Jurchison Ashley R. RobinsonAltimmune, Investor Relations LifeSci Advisors, LLCPhone: 410-474-8200 617-430-7577sjurchison@altimmune.com arr@lifesciadvisors.com